In the realm of oncology, City of Hope®, one of the United States’ most distinguished cancer research and treatment organizations, is set to make a significant impact at the forthcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. This prestigious conference, convening in Chicago and virtually from May 30 to June 3, will bring together nearly 45,000 oncology professionals globally to delve into the latest scientific breakthroughs and educational advancements that are transforming cancer care. With its National Medical Center recognized among the Top 5 “Best Hospitals” nationwide for cancer care by U.S. News & World Report, City of Hope will present groundbreaking research that could redefine therapeutic strategies and clinical outcomes across multiple cancer types.
The theme for this year’s ASCO assembly, “Driving Knowledge to Action. Building a Better Future,” underscores the critical nexus between cutting-edge research and patient-centered clinical application. City of Hope’s delegation is poised to contribute robust data sets and innovative research paradigms that spotlight precision oncology, novel therapeutic agents, and advanced management approaches for various malignancies including breast, pancreatic, colorectal, prostate, kidney, and hematologic cancers. Moreover, the emphasis on integrative and supportive care, such as palliative interventions, marks a progressive step towards holistic cancer treatment pathways that prioritize quality of life alongside survival metrics.
Central to City of Hope’s presentations are several key oral abstract and clinical symposium sessions that dissect tumor biology and therapeutic resistance in high-risk renal cell carcinoma. The IMmotion010 study, a randomized phase 3 trial exploring adjuvant atezolizumab versus placebo, will unveil comprehensive genomic characterizations of baseline and post-progression tumors. This analysis promises to elucidate mechanisms of immune evasion and tumor evolution, potentially guiding biomarker-driven treatment algorithms in kidney cancer. Leading this discourse is Dr. Sumanta Kumar Pal, a seasoned medical oncologist with extensive expertise in therapeutic research at City of Hope.
Complementing the genomic insights, City of Hope also emphasizes symptom science and palliative care, acknowledging the indispensable role these disciplines play in oncology. Dr. Tanyanika Phillips will chair a session focusing on the management of cancer-related symptoms and the integration of palliative care principles within standard oncology practice. This aligns with the growing recognition that addressing treatment side effects and symptom burden is fundamental to enhancing patient outcomes and curbing healthcare costs.
Dr. Heather Hampel’s involvement as chair and panelist in a session dedicated to hereditary cancer demonstrates City of Hope’s commitment to genetic risk stratification and precision prevention. By delving deeper into hereditary cancer risk and its clinical repercussions, the session will underscore advances in genetic counseling and germline testing that can personalize cancer surveillance and prophylactic strategies.
Rapid oral abstract sessions will highlight groundbreaking work in breast cancer therapy and hematologic malignancies. The investigation led by Dr. Hope S. Rugo into treatment rechallenge following trastuzumab-deruxtecan-related interstitial lung disease addresses a critical safety and efficacy question in metastatic breast cancer management. Understanding how to safely reintroduce this potent antibody-drug conjugate after pulmonary toxicity could expand therapeutic options for patients with resistant disease.
In leukemia research, Dr. Ibrahim T. Aldoss presents a post hoc analysis from the Phase 3 PhALLCON trial regarding minimal residual disease (MRD) negativity after induction therapy. MRD status serves as a highly sensitive biomarker predictive of relapse and survival, and optimizing treatment to achieve MRD negativity is a paramount goal in acute leukemia management. These findings can expedite the adoption of MRD-guided therapeutic decision-making.
Innovations in myeloma treatment will be critically discussed through City of Hope’s participation as a discussant in sessions exploring novel therapeutic avenues targeting plasma cell dyscrasias. Dr. Amrita Krishnan’s expertise enhances the dialogue surrounding emerging regimens and biomarker-driven interventions aimed at improving long-term disease control and patient quality of life in multiple myeloma.
Educational sessions curated by City of Hope further underscore emerging challenges in oncology. Dr. Hope S. Rugo’s presentation on managing endocrine toxicities serves to equip oncologists with best practices for mitigating adverse effects related to novel breast cancer therapies. This is pivotal as new agents with complex side effect profiles enter clinical use, requiring nuanced management strategies to maintain treatment adherence.
Pediatric oncology survivors’ morbidity reduction is addressed in a session led by Dr. Saro H. Armenian, who advocates for personalized intervention approaches. This focus highlights survivorship care as a critical extension of cancer therapy, addressing long-term consequences of childhood cancer treatment through tailored risk assessment and supportive care techniques.
Integrative oncology is also represented, with Dr. Krisstina Gowin presenting evidence-based guidelines for the management of cancer-associated pain, fatigue, and depression. By operationalizing ASCO’s supportive care guidelines into real-world practice, these sessions promote holistic, patient-centered care models that integrate conventional and complementary modalities.
Poster presentations extend the scope of City of Hope’s research portfolio, showcasing innovative clinical trial data across metastatic breast cancer, pancreatic ductal adenocarcinoma, colorectal cancer, and genitourinary malignancies. Notably, the NAPOLI 3 Phase 3 trial final overall survival analysis in metastatic pancreatic cancer, presented by Dr. Vincent Chung, offers fresh perspectives on treatment efficacy and long-term survival characteristics. Similarly, evaluations of novel immunotherapies and combinatorial regimens in kidney and prostate cancers provide important insights into optimizing sequencing and combination strategies.
Recognition of City of Hope faculty members such as Drs. Lorna Rodriguez-Rodriguez and Stacy W. Gray, who were inducted as fellows of the American Society of Clinical Oncology (FASCO), reflects the institution’s dedication to leadership in oncology research, education, and clinical excellence. This honor acknowledges their pivotal roles in fostering innovation and advancing standards of care to conquer cancer effectively.
City of Hope’s integrated research-to-practice model, underscored by its NCI-designated comprehensive cancer center, continues to influence oncology globally. The institution’s contributions at the 2025 ASCO Annual Meeting epitomize a mission-driven commitment to transforming complex cancer data into actionable clinical applications that improve patient survival and wellbeing. By converging basic science, translational research, and clinical expertise, City of Hope underscores the future of oncology—a future where knowledge unequivocally drives transformative cancer care.
As oncology confronts the challenges of heterogeneity, resistance mechanisms, and survivorship complexities, City of Hope’s broad research landscape—from molecular tumor characterization to supportive care innovation—foreshadows a new horizon in personalized and effective cancer management worldwide.
Subject of Research: Oncology research and clinical advancements across multiple cancer types, including renal cell carcinoma, breast cancer, pancreatic cancer, colorectal cancer, prostate cancer, kidney cancer, blood cancers, and supportive care modalities.
Article Title: City of Hope Unveils Pioneering Oncology Research at 2025 ASCO Annual Meeting
News Publication Date: Not specified in the provided content
Web References:
References: Not explicitly provided in the content
Image Credits: Not provided
Keywords: Oncology, Cancer Research, Precision Medicine, Immunotherapy, Hematologic Malignancies, Breast Cancer, Pancreatic Cancer, Colorectal Cancer, Prostate Cancer, Kidney Cancer, Clinical Trials, Supportive Care, Palliative Care
